Switching to, then stopping treatment with nilotinib for CML patients.
Research type
Research Study
Full title
A prospective, randomized, open label, two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia positive CML after two different durations of consolidation treatment with nilotinib 300mg BID.
IRAS ID
146148
Contact name
Jane Apperley
Contact email
Sponsor organisation
Novartis Pharma Services AG
Eudract number
2012-005124-15
REC name
London - Hampstead Research Ethics Committee
REC reference
14/LO/0521
Date of REC Opinion
23 May 2014
REC opinion
Further Information Favourable Opinion